If you are not happy with the results below please do another search
Roche subsidiary Genentech on Wednesday released data from the Phase III OCARINA II study, showing that its investigational subcutaneous formulation for Ocrevus (ocrelizumab) strongly reduced relapses and brain lesions in patients with relapsing or primary progressive multiple sclerosis.
Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active psoriatic arthritis in pediatric and adult patients. Unlike Stelara, however, Selarsdi is not approved for Crohn’s disease and ulcerative colitis.
The German cartel office has approved a deal by Denmark’s Novo Nordisk (NOVOb.CO) to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.
Cerevel Therapeutics reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
With continued success, Elahere will not only infiltrate the endometrial cancer market but also pave the way for future treatment strategies with an ADC and immunotherapy combination, says GlobalData.
“The FDA Fast Track Designation for AB-1002 is an important accomplishment for the clinical development of this program and highlights our goal of bringing potentially effective treatments to patients with advanced congestive heart failure,” said Canwen Jiang, MD, PhD, Chief Development Officer and Chief Medical Officer, AskBio.
According to the agency’s website, most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand.
“Compliancy Group is the first of a cadre of HIPAA compliance resources vetted by the CHC to assist agencies working with healthcare covered entities to navigate the nuances of HIPAA, federal breach notification requirements, and evolving state privacy laws,” said Jim Potter, CHC executive director.
Peregrine Market Access, a full-service consulting, communications, and commercialization partner for the life sciences industry, announced the hiring of Mawais Farooqui as a data analyst and Lewis “Lewi” Clarke as an associate account executive.
Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations.